CLAIMS

1. A combination comprising one or more products which activate dopaminergic neurotransmission in the brain and of one or more CB1 antagonist azetidine derivatives of formula I:



(I)

wherein

either A:

R is CR_1R_2, $C=C(R_5)SO_2R_6$ or $C=C(R_7)SO_2alk$; wherein either R_1 is hydrogen and R_2 is $-C(R_8)(R_9)(R_{10})$, $-C(R_8)(R_{11})(R_{12})$, $-CO-NR_{13}R_{14}$, $-CH_2-CO-NR_{13}R_{14}$, $-CH_2-CO-R_6$, $-CO-R_6$, -CO-cycloalkyl, $-SO-R_6$, $-SO_2-R_6$, $-C(OH)(R_{12})(R_6)$, $-C(OH)(R_6)(alkyl)$, $-C(=NOalk)R_6$, $-C(=NO-CH_2-CH=CH_2)R_6$, $-CH_2-CH(R_6)NR_{31}R_{32}$, $-CH_2-C(=NOalk)R_6$, $-CH(R_6)NR_{31}R_{32}$, $-CH(R_6)NHSO_2alk$, $-CH(R_6)NHCONHalk$ or $-CH(R_6)NHCOalk$; or R_1 is alkyl, $NH-R_{15}$, cyano, $-S-alk-NR_{16}R_{17}$, $-CH_2-NR_{18}R_{19}$ or $-NR_{20}R_{21}$; and R_2 is $-C(R_8)(R_{11})(R_{12})$;

R_3 and R_4, which are identical or different, independently are either alkyl, cycloalkyl, aryl chosen from phenyl, naphthyl or indenyl, wherein aryl being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, -CO-alk, cyano, -COOH, -COOalk, $-CONR_{22}R_{23}$, $-CO-NH-NR_{24}R_{25}$, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl,

alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl or -alk-$NR_{24}R_{25}$; or heteroaryl chosen from benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydroxybenzofuryl, 2,3-dihydrobenzothienyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, pyrimidinyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, thiazolyl and thienyl, wherein heteroaryl is unsubstituted or substituted by one or more halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, -COOH, -COOalk, -CO-NH-$NR_{24}R_{25}$, -$CONR_{22}R_{23}$, -alk-$NR_{24}R_{25}$, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl or hydroxyalkyl;

R_5 is hydrogen or alkyl;

R_6 is Ar_1 or Het_1;

R_7 is cycloalkyl, heterocycloalkyl or heterocyclenyl optionally substituted by -CSO-phenyl;

R_8 is hydrogen or alkyl;

R_9 is -$CO-NR_{26}R_{27}$, -COOH, -COOalk, -CH_2OH, -NH-CO-NH-alk, -CH_2-NHR_{28} or -NHCOOalk;

R_{10} is Ar_1 or Het_1;

R_{11} is -SO_2-alk, -SO_2-Ar_1 or -SO_2-Het_1;

R_{12} is hydrogen, Ar_1 or Het_1;

R_{13} is hydrogen or alkyl;

R_{14} is Ar_1, Het_1, -alk-Ar_1 or -alk-Het_1;

R_{15} is alkyl, cycloalkyl or -alk-$NR_{29}R_{30}$;

R_{16} and R_{17}, which are identical or different, independently are either hydrogen or alkyl; or

R_{16} and R_{17} taken together with the nitrogen atom to which they are attached form a saturated or unsaturated 3 to 10 ring membered mono- or 5 to 10 ring membered bicyclic heterocycle, optionally comprising one or more other heteroatoms chosen from oxygen, sulfur and nitrogen and optionally substituted by one or more alkyl;

R_{18} is hydrogen or alkyl;

R_{19} is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, $-SO_2$alk, -CO-NHalk or -COOalk; or

R_{18} and R_{19} taken with the nitrogen atom to which they are attached form a saturated or unsaturated 3 to 10 ring membered mono- or 5 to 10 ring membered bicyclic heterocycle, optionally comprising one or more heteroatoms chosen from oxygen, sulfur and nitrogen and optionally substituted by one or more alkyl;

$-NR_{20}R_{21}$ is a saturated or unsaturated monocyclic heterocycle having 3 to 8 ring members and optionally comprising another heteroatom chosen from oxygen, nitrogen and sulfur;

R_{22} and R_{23}, which are identical or different, independently are hydrogen or alkyl; or

R_{22} and R_{23} taken together with the nitrogen atom to which they are attached form a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one more alkyl;

R_{24} and R_{25}, which are identical or different, independently are hydrogen, alkyl, -COOalk,

cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl; or

R_{24} and R_{25} taken together with the nitrogen atom to which they are attached form a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, -alk-O-alk or $-CO-NH_2$;

R_{26} and R_{27}, which are identical or different, independently are hydrogen, alkyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, -alk-COOalk, $-alk-Ar_1$, $alk-Het_1$, Het_1 or $-alk-N(alk)_2$; or

R_{26} and R_{27} taken together with the nitrogen atom to which they are attached form a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members and optionally comprising one or more heteroatoms chosen from oxygen, sulfur and nitrogen and optionally substituted by one or more alkyl, alkoxy or halogen;

R_{28} is $-CH_2$-alk, benzyl, $-SO_2$alk, -CONHalk, -COalk, cycloalkylalkylcarbonyl, cycloalkylcarbonyl or $-CO-(CH_2)_nOH$, wherein n is an integer from 1 to 3;

R_{29} and R_{30}, which are identical or different, independently are hydrogen or alkyl; or

R_{29} and R_{30} taken together with the nitrogen atom to which they are attached form a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and

nitrogen and optionally being substituted by one or more alkyl radicals;

R_{31} and R_{32}, which are identical or different, independently are hydrogen, alkyl, Ar_1 or -alk-Ar_1; or

R_{31} and R_{32} taken together with the nitrogen atom to which they are attached form a heterocycle chosen from aziridinyl, azetidinyl, pyrrolidinyl and piperidinyl;

Ar_1 is phenyl or naphthyl optionally substituted by one or more substituents chosen from halogen, alkyl, alkoxy, -CO-alk, cyano, -COOH, -COOalk, -$CONR_{22}R_{23}$, -CO-NH-$NR_{24}R_{25}$, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl, -alk-$NR_{24}R_{25}$, -$NR_{24}R_{25}$, alkylthioalkyl, formyl, hydroxyl, CF_3, OCF_3, Het_1, O-alk-NH-cycloalkyl or SO_2NH_2;

Het_1 is a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members and comprising one or more heteroatoms chosen from oxygen, sulfur and nitrogen and optionally substituted by one or more halogen, alkyl, alkoxy, alkoxycarbonyl, -$CONR_{22}R_{23}$, hydroxyl, hydroxyalkyl, oxo or SO_2NH_2;

or B: wherein

R is CHR_{33}; wherein

R_{33} is -$NHCOR_{34}$ or -$N(R_{35})$-Y-R_{36};

Y is CO or SO_2;

R_3 and R_4, which are identical or different, are either aryl chosen from phenyl, naphthyl and indenyl, wherein aryl being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl,

trifluoromethoxy, -CO-alk, cyano, -COOH, -COOalk, $-CONR_{37}R_{38}$, $-CO-NH-NR_{39}R_{40}$, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl or $-alk-NR_{37}R_{38}$; or heteroaryl chosen from benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydro-benzofuryl, 2,3-dihydro-benzothienyl, pyrimidinyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, thiazolyl and thienyl, wherein heteroaryl being unsubstituted or substituted by halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, -COOH, -COOalk, $-CO-NH-NR_{39}R_{40}$, $-CONR_{37}R_{38}$, $-alk-NR_{39}R_{40}$, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl or hydroxyalkyl;

R_{34} is $-alk-SO_2-R_{41}$, $-alk-SO_2-CH=CH-R_{41}$, Het_2 substituted by $-SO_2-R_{41}$ or phenyl substituted by $-SO_2-R_{41}$ or $-alk-SO_2-R_{41}$;

R_{35} is hydrogen or alkyl;

R_{36} is phenylalkyl, Het_2 or Ar_2;

R_{37} and R_{38}, which are identical or different, independently are hydrogen or alkyl; or

R_{37} and R_{38} taken together with the nitrogen atom to which they are attached form a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl;

R_{39} and R_{40}, which are identical or different, independently are hydrogen or alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl; or

R_{39} and R_{40} taken together with the nitrogen atom to which they are attached form a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, -alk-O-alk or $-CO-NH_2$;

R_{41} is alkyl, Ar_2 or Het_2;

Ar_2 is phenyl, naphthyl or indenyl radical, these radicals optionally being substituted by one or more halogen, alkyl, alkoxy, cyano, -CO-alk, -COOH, -COOalk, $-CONR_{42}R_{43}$, $-CO-NH-NR_{44}R_{45}$, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, $-alk-NR_{44}R_{45}$, $-NR_{44}R_{45}$, alkylthioalkyl, formyl, hydroxyl, hydroxyalkyl, Het_2, -O-alk-NH-cycloalkyl, OCF_3, CF_3, -NH-CO-alk, $-SO_2NH_2$, $-HN-COCH_3$, -NH-COOalk or Het_2 or else on two adjacent carbon atoms by a dioxymethylene;

Het_2 is a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members and comprising one or more heteroatoms chosen from oxygen, sulfur and nitrogen optionally substituted by one or more alkyl, alkoxy, vinyl, halogen, alkoxycarbonyl, oxo, hydroxyl, OCF_3 or CF_3, the nitrogenous heterocycles optionally being in their N-oxidized form;

R_{42} and R_{43}, which are identical or different, independently are hydrogen or alkyl; or

R_{42} and R_{43} taken together with the nitrogen atom to which they are attached form a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl;

R_{44} and R_{45}, which are identical or different, independently are hydrogen, alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl; or

R_{44} and R_{45} taken together with the nitrogen atom to which they are attached form a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, -alk-O-alk or $-CO-NH_2$;

or C: wherein

R is CHR_{46}, wherein

R_{46} is $-N(R_{47})R_{48}$, $-N(R_{47})-CO-R_{48}$ or $-N(R_{47})-SO_2R_{49}$;

R_3 and R_4, which are identical or different, represent either an aryl chosen from phenyl, naphthyl and indenyl, wherein aryl being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, -CO-alk, cyano, -COOH, -COOalk, $-CONR_{50}R_{51}$, $-CO-NH-NR_{52}R_{53}$, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl or $-alk-NR_7R_8$; or a heteroaryl chosen from benzofuryl, benzothiazolyl,

benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, pyrimidyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, thiazolyl and thienyl, wherein heteroaryl being unsubstituted or substituted by halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, -COOH, -COOalk, -CO-NH-$NR_{52}R_{53}$, -$CONR_{50}R_{51}$, -alk-$NR_{52}R_{53}$, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl or hydroxyalkyl;

R_{47} is -$C(R_{54})(R_{55})$-Het_3, Het_3, -$C(R_{54})(R_{55})$-Ar_3, Ar_3, cycloalkyl or norbornyl;

R_{48} is hydrogen or hydroxyalkyl, -alk-COOalk, -alk-$CONR_{50}R_{51}$, -alk-$NR_{50}R_{51}$, alkoxy; Ar_3, Het_3, -CH_2Ar_3, -CH_2Het_3 or alkyl, optionally substituted with one or more halogen;

R_{49} is hydroxyalkyl, -alk-COOalk, -alk-$CONR_{50}R_{51}$, -alk-$NR_{50}R_{51}$, alkoxy, Ar_3, Het_3, -CH_2Ar_3, -CH_2Het_3 or alkyl optionally substituted with one or more halogen;

R_{50} and R_{51}, which are identical or different, independently are hydrogen or alkyl; or

R_{50} and R_{51} taken together with the nitrogen atom to which they are attached form a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl;

R_{52} and R_{53}, which are identical or different, independently are hydrogen or alkyl, -COOalk,

cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl; or

R_{52} and R_{53} taken together with the nitrogen atom to which they are attached form a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, -alk-O-alk or $-CO-NH_2$;

R_{54} is hydrogen, hydroxyalkyl, -alk-COOalk, $-alk-CONR_{50}R_{51}$, $-alk-NR_{50}R_{51}$, alkoxyalkyl, Ar_3, Het_3, $-CH_2Ar_3$, $-CH_2Het_3$ or alkyl optionally substituted with one or more halogen;

R_{55} is hydrogen or hydroxyalkyl, -alk-COOalk, $-alk-CONR_{50}R_{51}$, $-alk-NR_{50}R_{51}$, alkoxyalkyl or alkyl optionally substituted with one or more halogen; or

R_{54} and R_{55} taken together with the carbon atom to which they are attached form a saturated mono- or bicyclic ring having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl;

Ar_3 is phenyl, naphthyl or indenyl, optionally being substituted by one or more halogen, alkyl, alkoxy, -CO-alk, cyano, -COOH, -COOalk, $-CONR_{56}R_{57}$, $-CO-NH-NR_{58}R_{59}$, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, $-alk-NR_{58}R_{59}$, $-NR_{58}R_{59}$, alkylthioalkyl, formyl, CF_3, OCF_3, Het_3, -O-alk-NH-cycloalkyl, SO_2NH_2, hydroxyl, hydroxyalkyl, -NHCOalk or -NHCOOalk

or on 2 adjacent carbon atoms by dioxymethylene;

Het_3 is a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members and comprising one or more heteroatoms chosen from oxygen, sulfur and nitrogen optionally substituted by one or more alkyl, alkoxy, halogen, alkoxycarbonyl, oxo or hydroxyl, the nitrogenous heterocycles optionally being in their N-oxidized form;

R_{56} and R_{57}, which are identical or different, independently are hydrogen or alkyl radical; or

R_{56} and R_{57} taken together with the nitrogen atom to which they are attached form a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl;

R_{58} and R_{59}, which are identical or different, independently are hydrogen or alkyl; or

R_{58} and R_{59} taken together with the nitrogen atom to which they are attached form a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl;

alk is an alkyl or alkylene radical; and wherein the alkyl, alkylene and alkoxy radicals have straight or branched chains and comprise 1 to 6 carbon atoms, the cycloalkyl radicals comprise 3 to 10 carbon atoms and the

heterocycloalkyl and heterocyclenyl radicals comprise 3 to 10 carbon atoms; or an optical isomer thereof or a pharmaceutically acceptable salt thereof.

2. The combination according to claim 1, wherein the compound of formula (I) is chosen from the following compounds:
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide or
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, or a pharmaceutically acceptable salt thereof.

3. The combination according to claim 1, wherein the product which activates dopaminergic neurotransmission in the brain is chosen from the following compounds:
bromocriptine, cabergoline, adrogolide, BAM-1110, duodopa, levodopa, dopadose, CHF1512, PNU-95666, ropinirole, pramipexole, rotigotine, spheramine, TV1203, uridine, rasagiline, selegiline, SL340026, tolcapone or entacapone.

4. The combination according to claim 1, wherein the product which activates dopaminergic neurotransmission in the brain is levodopa and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide.

5. The combination according to claim 1, wherein the product which activates dopaminergic neurotransmission in the brain is ropinirole and the CB1 antagonist is N-{1-[bis(4-

chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide.

6. The combination according to claim 1, wherein the product which activates dopaminergic neurotransmission in the brain is bromocriptine and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide.

7. The combination according to claim 1, wherein the product which activates dopaminergic neurotransmission in the brain is pramixepole and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide.

8. The combination according to claim 1, wherein the product which activates dopaminergic neurotransmission in the brain is rasagiline and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide.

9. The combination according to claim 1, wherein the product which activates dopaminergic neurotransmission in the brain is entacapone and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide.

10. The combination according to claim 1, characterized in that the product which activates dopaminergic neurotransmission in the brain is levodopa and the CB1 antagonist is

N-{1-[bis(4-chloro-phenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)-methylsulfonamide.

11. The combination according to claim 1, wherein the product which activates dopaminergic neurotransmission in the brain is ropinirole and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.

12. The combination according to claim 1, wherein the product which activates dopaminergic neurotransmission in the brain is bromocriptine and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.

13. The combination according to claim 1, wherein the product which activates dopaminergic neurotransmission in the brain is pramixepole and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.

14. The combination according to claim 1, whrein the product which activates dopaminergic neurotransmission in the brain is rasagiline and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.

15. The combination according to claim 1, wherein the product which activates dopaminergic neurotransmission in the brain is entacapone and the CB1 antagonist is

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.

16. A method of treating Parkinson's disease in a patient comprising administering to said patient a therapeutically effective amount of a combination of a product which activates dopaminergic neurotransmission in the brain and one or more CB1 antagonists of formula (I) as defined in claim 1, optionally in combination with a pharmaceutically acceptable carrier.

17. The method according to claim 16, wherein the compound of formula (I) as defined in claim 1 is chosen from the following compounds:
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide, or
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, or a pharmaceutically acceptable salt thereof.

18. The method according to claim 16, wherein the product which activates dopaminergic neurotransmission in the brain is chosen from the following compounds:
bromocriptine, cabergoline, talipexole, adrogolide, BAM-1110, duodopa, levodopa, dopadose, CHF1301, CHF1512, PNU-95666, ropinirole, pramipexole, rotigotine, spheramine, TV1203, uridine, rasagiline, selegiline, SL340026, tolcapone or entacapone.

19. The method according to claim 16, wherein said product and said compound of formula (I) as defined in claim 1 are administered either

simultaneously, separately or spread out over time.

20. A pharmaceutical composition comprising one or more products which activate dopaminergic neurotransmission in the brain and one or more CB1 antagonists of formula (I) as defined in claim 1 in combination with a compatible and pharmaceutically acceptable vehicle.

21. The pharmaceutical composition according to claim 20, wherein the compound of formula (I) as defined in claim 1 is chosen from the following compounds: N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide, or N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, or a pharmaceutically acceptable salt thereof.

22. The pharmaceutical composition according to claim 20, wherein the product which activates dopaminergic neurotransmission in the brain is chosen from the following compounds: bromocriptine, cabergoline, talipexole, adrogolide, BAM-1110, duodopa, levodopa, dopadose, CHF1301, CHF1512, PNU-95666, ropinirole, pramipexole, rotigotine, spheramine, TV1203, uridine, rasagiline, selegiline, SL340026, tolcapone or entacapone.

23. The pharmaceutical composition according to claim 20, wherein the product which activates dopaminergic neurotransmission in the brain is levodopa and the CB1 antagonist is

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide.

24. The pharmaceutical composition according to claim 20, wherein the product which activates dopaminergic neurotransmission in the brain is ropinirole and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide.

25. The pharmaceutical composition according to claim 20, wherein the product which activates dopaminergic neurotransmission in the brain is bromocriptine and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide.

26. The pharmaceutical composition according to claim 20, wherein the product which activates dopaminergic neurotransmission in the brain is pramixepole and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide.

27. The pharmaceutical composition according to claim 20, wherein the product which activates dopaminergic neurotransmission in the brain is rasagiline and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide.

28. The pharmaceutical composition according to claim 20, wherein the product which activates dopaminergic neurotransmission in the brain is entacapone and the CB1 antagonist is

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide.

29. The pharmaceutical composition according to claim 20, wherein the product which activates dopaminergic neurotransmission in the brain is levodopa and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.

30. The pharmaceutical composition according to claim 20, wherein the product which activates dopaminergic neurotransmission in the brain is ropinirole and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.

31. The pharmaceutical composition according to claim 20, wherein the product which activates dopaminergic neurotransmission in the brain is bromocriptine and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.

32. The pharmaceutical composition according to claim 20, wherein the product which activates dopaminergic neurotransmission in the brain is pramixepole and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.

33. The pharmaceutical composition according to claim 20, wherein the product which activates dopaminergic neurotransmission in the brain is rasagiline and the CB1 antagonist is

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.

34. The pharmaceutical composition according to claim 20, wherein the product which activates dopaminergic neurotransmission in the brain is entacapone and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.

35. The pharmaceutical composition according to claim 20 for a simultaneous use, separate use or use spread out over time.

36. The pharmaceutical composition according to claim 20 wherein the CB1 antagonist of formula (I) as defined in claim 1 is present in an amount of from about 0.1 mg to about 500 mg.